Pexidartinib: First Approval

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Tenosynovial giant cell tumor (TGCT) is a rare neoplastic proliferation that can cause severe morbidity and functional limitations.
• Surgical intervention is the primary treatment for TGCT but is not always feasible or effective.
• Pexidartinib, a small molecule tyrosine kinase inhibitor, targets key signaling pathways implicated in TGCT pathogenesis.

Purpose of the Study:

• To summarize the development of pexidartinib (TURALIO™).
• To highlight the milestones leading to its FDA approval for TGCT treatment.
• To provide an overview of pexidartinib's mechanism of action and clinical investigation.

Main Methods:

• Review of preclinical data and clinical trial results, including the Phase III ENLIVEN trial.
• Analysis of pexidartinib's selective inhibition of CSF1 receptor, KIT, and FLT3-ITD.
• Summary of regulatory submission and approval process by the US FDA.

Main Results:

• Pexidartinib demonstrated significant efficacy in adult patients with symptomatic TGCT.
• The FDA approved pexidartinib capsules in August 2019 for TGCT treatment in patients not amenable to surgical improvement.
• Positive outcomes from the ENLIVEN trial formed the basis for regulatory approval.

Conclusions:

• Pexidartinib represents a significant therapeutic advancement for patients with TGCT.
• The drug's targeted mechanism offers a new treatment option for this rare tumor.
• Ongoing investigations explore pexidartinib's potential in other malignancies.